Inactive Instrument

Analyst Reco. Sarepta Therapeutics Inc Nasdaq

Equities

US0023461041

End-of-day quote Nasdaq Other stock markets
- ^USD	-

14/05	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	MT
02/05	Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	14/05	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating	02/05	MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating	02/05	MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating	01/03	MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating	29/02	MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating	29/02	MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating	29/02	MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $145 From $130, Keeps Buy Rating	14/02	MT
BMO Capital Starts Sarepta Therapeutics With Outperform Rating, $170 Price Target	31/01	MT
RBC Trims Price Target on Sarepta Therapeutics to $151 From $155, Keeps Outperform Rating	25/01	MT
Needham Raises Price Target on Sarepta Therapeutics to $140 From $93, Keeps Buy Rating	10/01	MT
RBC Raises Price Target on Sarepta Therapeutics to $155 From $148, Keeps Outperform Rating	03/01	MT
Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Buy Rating, $109 Price Target	12/12	MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors	21/11	MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors	21/11	MT
Needham Raises Price Target on Sarepta Therapeutics to $93 From $82, Keeps Buy Rating	02/11	MT
Cantor Fitzgerald Downgrades Sarepta Therapeutics to Neutral From Overweight, Cuts Price Target to $40 From $166	31/23/31	MT
Morgan Stanley Adjusts Price Target on Sarepta Therapeutics to $146 From $183, Maintains Overweight Rating	31/23/31	MT
Oppenheimer Downgrades Sarepta Therapeutics to Perform From Outperform	31/23/31	MT
Needham Adjusts Sarepta Therapeutics Price Target to $82 From $185, Maintains Buy Rating	31/23/31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sarepta Therapeutics Inc Nasdaq

Equities

US0023461041

Analyst Reco.

Filters